<qa>  What is the primary objective of PHENTPM ER?This is an exploratory open-label trial of PHENTPM ER Qsymia in BED. It is hypothesized that PHENTPM ER Qsymia will be an effective, safe, and well tolerated treatment for BED and propose to conduct a 1-site, 12-week, open-label, flexible dose study of PHENTPM ER Qsymia in 10 outpatients, ages 18 through 65 years, with BED. It is also hypothesized that PHENTPM ER Qsymia will reduce weight and binge eating behavior, and will be well tolerated. The primary objective is to show that PHENTPM ER Qsymia along with nutritional and lifestyle modification counseling is effective in reducing weight in overweight or obese patients with BED. Secondary objectives are to show that PHENTPM ER Qsymia is effective in reducing frequency of binge eating episodes and associated eating psychopathology and is safe and well tolerated in patients with BED. 